Agios Pharmaceuticals Inc. Stock
A loss of -2.380% shows a downward development for Agios Pharmaceuticals Inc..
Agios Pharmaceuticals Inc. is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
With a target price of 34 € there is a positive potential of 38.21% for Agios Pharmaceuticals Inc. compared to the current price of 24.6 €.
So far the community has only identified positive things for Agios Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -2.380% | 5.000% | 6.780% | -16.000% | 8.621% | 5.000% | -48.832% |
| Ligand Pharmaceuticals | 3.770% | 8.000% | 14.894% | 127.368% | 30.120% | 208.571% | 121.903% |
| United Therapeutics | 0.590% | 1.616% | -1.709% | 91.163% | 10.367% | 121.617% | 234.468% |
| Ionis Pharmaceuticals Inc. | 0.060% | 1.307% | -1.089% | 97.085% | -6.474% | 67.970% | 102.485% |
Comments
Agios Pharmaceuticals (AGIO) had its price target lowered by Bank of America Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (AGIO) had its price target lowered by Truist Financial Corporation from $39.00 to $36.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (AGIO) had its price target lowered by Bank of America Corporation from $44.00 to $41.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
News
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
Key Points
- Interested in Agios Pharmaceuticals, Inc.? Here are five stocks we like better.
- Agios said its rare hematology strategy is gaining momentum, pointing to a “very strong” early launch
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) rose by 11.2% this week, putting the stock into positive territory for the year. The move comes after a well-received first-quarter earnings report
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
Agios Pharmaceuticals (NASDAQ: AGIO) was a standout stock in the healthcare sector on Hump Day. Investors eagerly snapped up the company's shares after it unveiled its latest quarterly earnings